Form 4: Labcorp CMO nets 2,158 shares from PSU vesting

Labcorp EVP and CMO Amy B. Summy received 3,994 shares from a 2023 performance award and withheld 1,836 shares for taxes, lifting her direct holdings to 7,879.5 shares.

Summary

• On 2026-03-26, EVP and Chief Marketing Officer Amy B. Summy acquired 3,994 Labcorp common shares at $0 via a performance award granted on 2023-02-07 for the three-year period ended 2025-12-31.
• On the same date, 1,836 shares were withheld at $268.38 to satisfy tax withholding obligations (transaction code F).
• Net increase in beneficial ownership: 2,158 shares; post-transaction direct holdings: 7,879.5 shares.
• No derivative securities were reported in this filing.
• The filing was signed by attorney-in-fact on 2026-03-30.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive given the insider’s net share increase and completion of a performance cycle, though it contains no operational results.

Positives

• Insider net ownership increased by 2,158 shares, signaling greater alignment with shareholders.
• Multi-year performance award vested for the cycle ending 2025-12-31, reflecting completion of the performance period.
• No open-market sale occurred; taxes were satisfied via share withholding (code F).

Negatives

• Equity award results in incremental share issuance to the executive; magnitude of company-wide dilution is not specified.
• No operational, revenue, or earnings data provided in this filing.

Future Outlook

No forward-looking statements or guidance; this reports insider equity award vesting and tax withholding.

Management Comments

• Shares acquired on 2026-03-26 pursuant to a performance award granted on 2023-02-07 relating to performance during the three-year period ended 2025-12-31.
• Stock withholding was used to satisfy tax withholding obligations.

Industry Context

StockSavvy.ai notes that PSU vesting and tax withholding are standard across healthcare and life sciences peers (e.g., Quest Diagnostics, Thermo Fisher, Danaher), aligning executive incentives with multi-year performance outcomes.

Comparison to Industry Standards

• In line with peers such as Quest Diagnostics (DGX), Thermo Fisher (TMO), and Danaher (DHR), Labcorp uses multi-year performance share units that vest based on multi-year metrics, followed by net share settlement for taxes.
• Use of transaction code F (share withholding for taxes) is a common mechanism to avoid open-market sales at vesting, consistent with large-cap governance practices.
• The scale of net acquisition (2,158 shares) appears typical for an EVP-level award, comparable to mid-to-senior executive PSU vestings observed among S&P 500 healthcare companies.

Stakeholder Impact

• Increases executive share ownership, further aligning incentives with shareholders.
• No open-market selling pressure; taxes satisfied through share withholding.
• Minimal immediate impact on day-to-day operations; transaction pertains to compensation.

Key Dates

Keywords

Labcorp, LH, Form 4, insider transaction, performance share units, executive compensation, stock withholding, beneficial ownership, Amy B. Summy, healthcare diagnostics